#184

OK so from a lifespan point of view, everolimus seems useless (vs sirolimus).

The question of the potentially better BBB crossing remains. However, sirolimus seems beneficial according to this trial: Rapamycin as a preventive intervention for Alzheimer’s disease in APOE4 carriers: targeting brain metabolic and vascular restoration

#185

I am not myself sure that everolimus would be necessarily worse than sirolimus. My reason for concentrating on Rapamycin is that we have more knowledge about its potential risks and hence if I take a high dose I am more likely to be aware of any negative consequences and how to handle them.

Also there is only so much experimentation that can be done. My experiments take multiple weeks at times and I really cannot slot in an alternative to rapamycin that has much the same mechanism.

I am also not persuaded of the argument that rapamycin does not cross the BBB. It probably crosses at a lower rate.

I don’t think that any one molecule (citrate, rapamycin, menaquinone-7, melatonin) is the solution to repairing the mitochondrial dna. I think a combination in a cyclical manner is going to produce the optimal results.

1 Like